OMass Therapeutics has announced an exclusive collaboration and license agreement with Genentech, granting rights to develop and commercialize its preclinical oral small molecule program targeting inflammatory bowel disease (IBD). This partnership underscores the growing interest in innovative treatments for IBD, which affects nearly 8 million individuals globally.
OMass’s CEO, Ros Deegan, highlighted the significance of their OdyssION platform in advancing a first-in-class therapeutic with a unique mechanism of action. The collaboration will see OMass lead the initial preclinical development, while Genentech will handle clinical development and commercialization. The agreement includes an upfront payment of $20 million and potential milestone payments exceeding $400 million, along with tiered royalties on net sales.
This collaboration not only reflects OMass’s commitment to addressing unmet medical needs in IBD but also illustrates the strategic alignment between biotech innovation and established pharmaceutical expertise, potentially accelerating the development of transformative therapies in the immunology space.
